Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cyclophosphamide and Sirolimus for Metastatic Differentiated Thyroid Cancer
NCT03099356Phase 2Recruiting
- Sponsor
- University of Michigan Rogel Cancer Center
- Start
- Apr 2017
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of cyclophosphamide, sirolimus in Differentiated Thyroid Cancer (DTC), sponsored by University of Michigan Rogel Cancer Center. Started Apr 2017; status: recruiting.
02
Drugs
cyclophosphamidesirolimus
03
Conditions
Differentiated Thyroid Cancer (DTC)
Beyond the preview
Go deeper on NCT03099356.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03099356.